Symbols / AGIO Stock $28.00 -0.18% Agios Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
AGIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Brian M. Goff M.B.A.
Exch · Country NMS · United States
Market Cap 1.67B
Enterprise Value 638.87M
Income -412.78M
Sales 54.03M
FCF (ttm) -267.97M
Book/sh 20.41
Cash/sh 14.58
Employees 539
Insider 10d —
IPO Jul 24, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.98
PEG —
P/S 30.82
P/B 1.37
P/C —
EV/EBITDA -1.37
EV/Sales 11.82
Quick Ratio 10.53
Current Ratio 11.46
Debt/Eq 3.37
LT Debt/Eq —
EPS (ttm) -7.26
EPS next Y -4.68
EPS Growth —
Revenue Growth 86.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-04-29
ROA -19.93%
ROE -30.20%
ROIC —
Gross Margin 0.00%
Oper. Margin -6.09%
Profit Margin 0.00%
Shs Outstand 59.47M
Shs Float 49.74M
Insider Own 1.09%
Instit Own 104.54%
Short Float 12.17%
Short Ratio 6.79
Short Interest 7.08M
52W High 46.00
vs 52W High -39.13%
52W Low 22.24
vs 52W Low 25.90%
Beta 0.79
Impl. Vol. 62.16%
Rel Volume 1.24
Avg Volume 1.05M
Volume 1.31M
Target (mean) $41.12
Tgt Median $38.50
Tgt Low $28.00
Tgt High $60.00
# Analysts 8
Recom Buy
Prev Close $28.05
Price $28.00
Change -0.18%
About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$41.13
Mean price target
2. Current target
$28.00
Latest analyst target
3. DCF / Fair value
$-81.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.00
Low
$28.00
High
$60.00
Mean
$41.13

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-30 main Truist Securities Buy → Buy $36
2026-04-21 main B of A Securities Buy → Buy $41
2026-04-20 main HC Wainwright & Co. Buy → Buy $50
2026-04-06 main JP Morgan Neutral → Neutral $36
2026-04-01 main Goldman Sachs Neutral → Neutral $32
2026-03-05 main Citigroup Buy → Buy $46
2026-02-12 main HC Wainwright & Co. Buy → Buy $65
2026-01-06 main JP Morgan Neutral → Neutral $25
2025-12-26 main Leerink Partners Outperform → Outperform $40
2025-12-24 main Truist Securities Buy → Buy $38
2025-12-24 main B of A Securities Buy → Buy $34
2025-12-24 main HC Wainwright & Co. Buy → Buy $62
2025-11-26 init Citigroup — → Buy $38
2025-11-24 init Truist Securities — → Buy $32
2025-11-21 main JP Morgan Neutral → Neutral $20
2025-11-20 down RBC Capital Outperform → Sector Perform $28
2025-11-20 main B of A Securities Buy → Buy $32
2025-11-20 up Leerink Partners Market Perform → Outperform $34
2025-11-20 main Goldman Sachs Neutral → Neutral $25
2025-11-20 main HC Wainwright & Co. Buy → Buy $48
News
RSS: Latest AGIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-02 GOFF BRIAN Chief Executive Officer — 19,068 $34.71 $661,850
2026-04-02 GOFF BRIAN Chief Executive Officer — 39,028 — —
2026-04-02 JONES CECILIA Chief Financial Officer — 3,141 $34.71 $109,024
2026-04-02 JONES CECILIA Chief Financial Officer — 8,500 — —
2026-04-02 GHEUENS SARAH Officer — 2,940 $34.71 $102,047
2026-04-02 GHEUENS SARAH Officer — 8,500 — —
2026-04-02 BURNS JAMES WILLIAM Officer — 3,280 $34.71 $113,849
2026-04-02 BURNS JAMES WILLIAM Officer — 8,500 — —
2026-04-02 MILANOVA TSVETA Officer — 3,262 $34.71 $113,224
2026-04-02 MILANOVA TSVETA Officer — 8,500 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
54.03
+48.03%
36.50
+36.07%
26.82
+88.36%
14.24
Operating Revenue
54.03
+48.03%
36.50
+36.07%
26.82
+88.36%
14.24
Cost Of Revenue
6.34
+52.34%
4.17
+44.57%
2.88
+69.07%
1.70
Reconciled Cost Of Revenue
6.34
+52.34%
4.17
+44.57%
2.88
+69.07%
1.70
Gross Profit
47.68
+47.47%
32.33
+35.05%
23.94
+90.99%
12.54
Operating Expense
519.82
+13.48%
458.07
+10.26%
415.43
+3.45%
401.58
Research And Development
339.54
+12.70%
301.29
+1.95%
295.53
+5.58%
279.91
Selling General And Administration
180.28
+14.99%
156.78
+30.76%
119.90
-1.45%
121.67
Total Expenses
526.16
+13.83%
462.24
+10.50%
418.31
+3.73%
403.29
Operating Income
-472.13
-10.90%
-425.74
-8.75%
-391.49
-0.63%
-389.05
Total Operating Income As Reported
-472.13
-10.90%
-425.74
-8.75%
-391.49
-0.63%
-389.05
EBITDA
-466.95
-11.16%
-420.08
-9.15%
-384.86
-1.15%
-380.48
Normalized EBITDA
-466.95
+69.06%
-1,509.22
-292.14%
-384.86
+25.73%
-518.19
Reconciled Depreciation
5.18
-8.42%
5.65
-14.65%
6.62
-22.66%
8.56
EBIT
-472.13
-10.90%
-425.74
-8.75%
-391.49
-0.63%
-389.05
Total Unusual Items
0.00
-100.00%
1,089.14
0.00
-100.00%
137.70
Total Unusual Items Excluding Goodwill
0.00
-100.00%
1,089.14
0.00
-100.00%
137.70
Special Income Charges
0.00
-100.00%
1,089.14
0.00
-100.00%
137.70
Restructuring And Mergern Acquisition
—
—
—
-127.85
Net Income
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Pretax Income
-413.80
-157.63%
717.97
+303.92%
-352.09
-51.89%
-231.80
Net Non Operating Interest Income Expense
56.38
+17.25%
48.08
+44.20%
33.34
+160.64%
12.79
Net Interest Income
56.38
+17.25%
48.08
+44.20%
33.34
+160.64%
12.79
Interest Income Non Operating
56.38
+17.25%
48.08
+44.20%
33.34
+160.64%
12.79
Interest Income
56.38
+17.25%
48.08
+44.20%
33.34
+160.64%
12.79
Other Income Expense
1.96
-99.82%
1,095.62
+17994.52%
6.05
-95.81%
144.45
Other Non Operating Income Expenses
1.96
-69.85%
6.49
+7.13%
6.05
-10.28%
6.75
Gain On Sale Of Business
0.00
-100.00%
1,089.14
0.00
-100.00%
137.70
Tax Provision
-1.02
-102.30%
44.24
0.00
0.00
Tax Rate For Calcs
0.00
-96.75%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
67.12
0.00
0.00
Net Income Including Noncontrolling Interests
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Net Income From Continuing Operation Net Minority Interest
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Net Income From Continuing And Discontinued Operation
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Net Income Continuous Operations
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Net Income Discontinuous Operations
—
—
0.00
0.00
Normalized Income
-412.78
-18.52%
-348.29
+1.08%
-352.09
+4.71%
-369.50
Net Income Common Stockholders
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Diluted EPS
-7.12
-161.17%
11.64
+283.89%
-6.33
-49.65%
-4.23
Basic EPS
-7.12
-160.03%
11.86
+287.36%
-6.33
-49.65%
-4.23
Basic Average Shares
57.97
+2.05%
56.81
+2.08%
55.65
+1.57%
54.79
Diluted Average Shares
57.97
+0.14%
57.89
+4.02%
55.65
+1.57%
54.79
Diluted NI Availto Com Stockholders
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Total Other Finance Cost
—
—
—
-12.79
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,297.22
-22.00%
1,663.20
+77.48%
937.12
-24.35%
1,238.72
Current Assets
942.05
-2.44%
965.60
+15.80%
833.84
+0.13%
832.77
Cash Cash Equivalents And Short Term Investments
854.42
-4.40%
893.71
+15.03%
776.93
-0.79%
783.12
Cash And Cash Equivalents
89.13
+16.90%
76.25
-13.56%
88.20
-36.66%
139.26
Other Short Term Investments
765.29
-6.38%
817.46
+18.69%
688.72
+6.97%
643.86
Receivables
10.58
+157.41%
4.11
+46.23%
2.81
+27.38%
2.21
Accounts Receivable
10.58
+157.41%
4.11
+46.23%
2.81
+27.38%
2.21
Other Receivables
—
—
—
—
Inventory
32.92
+19.21%
27.62
+44.77%
19.08
+124.63%
8.49
Raw Materials
0.09
-1.12%
0.09
+74.51%
0.05
0.00
Work In Process
30.25
+23.44%
24.51
+39.51%
17.57
+132.69%
7.55
Finished Goods
2.58
-14.55%
3.02
+107.14%
1.46
+54.67%
0.94
Prepaid Assets
—
—
—
—
Assets Held For Sale Current
—
—
—
—
Other Current Assets
44.13
+9.87%
40.16
+14.69%
35.02
-10.10%
38.95
Total Non Current Assets
355.17
-49.09%
697.60
+575.42%
103.28
-74.56%
405.95
Net PPE
41.23
-24.43%
54.55
-21.83%
69.79
-20.80%
88.12
Gross PPE
101.34
-8.74%
111.05
-8.99%
122.02
-11.70%
138.19
Accumulated Depreciation
-60.12
-6.40%
-56.50
-8.17%
-52.23
-4.31%
-50.07
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
30.45
-28.98%
42.88
-21.19%
54.41
-16.46%
65.13
Machinery Furniture Equipment
13.06
+6.79%
12.23
-0.54%
12.29
+2.95%
11.94
Construction In Progress
2.75
+206.24%
0.90
+47.53%
0.61
-7.46%
0.66
Other Properties
17.57
+0.22%
17.53
+0.55%
17.43
-24.80%
23.18
Leases
37.52
+0.00%
37.52
+0.65%
37.28
+0.00%
37.28
Investments And Advances
310.01
-51.43%
638.32
+2068.58%
29.43
-90.62%
313.87
Other Non Current Assets
3.93
-16.79%
4.72
+16.44%
4.06
+2.55%
3.96
Total Liabilities Net Minority Interest
104.11
-14.83%
122.24
-3.06%
126.10
-8.56%
137.90
Current Liabilities
82.21
+1.29%
81.16
+19.43%
67.95
+8.50%
62.63
Payables And Accrued Expenses
36.55
+6.13%
34.44
+15.90%
29.71
-3.71%
30.86
Payables
18.36
+4.80%
17.51
+79.08%
9.78
-47.46%
18.62
Accounts Payable
18.36
+10.29%
16.64
+70.17%
9.78
-47.46%
18.62
Current Accrued Expenses
18.20
+7.50%
16.93
-15.09%
19.93
+62.80%
12.24
Pensionand Other Post Retirement Benefit Plans Current
27.26
-8.92%
29.93
+28.85%
23.23
+28.32%
18.11
Total Tax Payable
0.00
-100.00%
0.87
0.00
—
Income Tax Payable
0.00
-100.00%
0.87
0.00
—
Current Debt And Capital Lease Obligation
18.39
+9.60%
16.78
+11.81%
15.01
+9.84%
13.66
Current Capital Lease Obligation
18.39
+9.60%
16.78
+11.81%
15.01
+9.84%
13.66
Total Non Current Liabilities Net Minority Interest
21.91
-46.69%
41.09
-29.34%
58.14
-22.76%
75.28
Liabilities Heldfor Sale Non Current
—
—
—
—
Long Term Debt And Capital Lease Obligation
21.82
-45.74%
40.21
-29.45%
56.99
-20.85%
72.00
Long Term Capital Lease Obligation
21.82
-45.74%
40.21
-29.45%
56.99
-20.85%
72.00
Other Non Current Liabilities
0.09
-89.77%
0.88
-23.88%
1.16
-64.75%
3.28
Stockholders Equity
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Common Stock Equity
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Capital Stock
0.07
+2.74%
0.07
+1.39%
0.07
+1.41%
0.07
Common Stock
0.07
+2.74%
0.07
+1.39%
0.07
+1.41%
0.07
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
74.67
+1.76%
73.37
+1.68%
72.16
+1.27%
71.26
Ordinary Shares Number
58.45
+2.26%
57.16
+2.16%
55.95
+1.64%
55.04
Treasury Shares Number
16.22
+0.00%
16.22
+0.00%
16.22
+0.00%
16.22
Additional Paid In Capital
2,555.04
+2.46%
2,493.81
+2.35%
2,436.52
+2.10%
2,386.32
Retained Earnings
-561.71
-277.18%
-148.92
+81.90%
-822.65
-74.82%
-470.56
Gains Losses Not Affecting Retained Earnings
2.19
+244.47%
-1.52
-244.22%
-0.44
+96.48%
-12.54
Treasury Stock
802.49
+0.00%
802.49
+0.00%
802.49
+0.00%
802.49
Other Equity Adjustments
2.19
+244.47%
-1.52
-244.22%
-0.44
+96.48%
-12.54
Total Equity Gross Minority Interest
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Total Capitalization
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Working Capital
859.85
-2.78%
884.44
+15.48%
765.88
-0.55%
770.14
Invested Capital
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Total Debt
40.21
-29.45%
56.99
-20.85%
72.00
-15.95%
85.66
Capital Lease Obligations
40.21
-29.45%
56.99
-20.85%
72.00
-15.95%
85.66
Net Tangible Assets
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Tangible Book Value
1,193.11
-22.57%
1,540.96
+90.00%
811.02
-26.33%
1,100.81
Available For Sale Securities
310.01
-51.43%
638.32
+2068.58%
29.43
-90.62%
313.87
Investmentin Financial Assets
310.01
-51.43%
638.32
+2068.58%
29.43
-90.62%
313.87
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-372.98
+4.33%
-389.84
-31.68%
-296.06
+4.34%
-309.48
Cash Flow From Continuing Operating Activities
-372.98
+4.33%
-389.84
-31.68%
-296.06
+4.34%
-309.48
Cash From Discontinued Operating Activities
—
—
0.00
0.00
Net Income From Continuing Operations
-412.78
-161.27%
673.73
+291.35%
-352.09
-51.89%
-231.80
Depreciation Amortization Depletion
5.18
-8.42%
5.65
-14.65%
6.62
-22.66%
8.56
Depreciation And Amortization
5.18
-8.42%
5.65
-14.65%
6.62
-22.66%
8.56
Other Non Cash Items
22.43
+102.56%
-877.61
-3209.87%
28.22
+123.94%
-117.86
Stock Based Compensation
52.55
+22.65%
42.85
-4.29%
44.77
-9.19%
49.30
Operating Gains Losses
-0.11
+99.94%
-200.21
-38234.48%
0.53
+1193.75%
-0.05
Gain Loss On Investment Securities
-0.12
+29.34%
-0.17
-496.43%
-0.03
—
Gain Loss On Sale Of PPE
0.01
+112.82%
-0.04
-107.05%
0.55
+1252.08%
-0.05
Change In Working Capital
-33.04
-67.15%
-19.77
-3.73%
-19.06
-15.97%
-16.43
Change In Receivables
-6.47
-397.92%
-1.30
-115.07%
-0.60
+65.66%
-1.76
Changes In Account Receivables
-6.47
-397.92%
-1.30
-115.07%
-0.60
+72.62%
-2.21
Change In Inventory
-5.30
+37.89%
-8.54
+19.31%
-10.58
-24.63%
-8.49
Change In Prepaid Assets
-3.17
+45.41%
-5.81
-251.60%
3.83
+2277.84%
-0.18
Change In Payables And Accrued Expense
-0.53
-104.72%
11.17
+173.41%
4.08
+124.52%
1.82
Change In Accrued Expense
-1.40
-137.95%
3.69
-71.18%
12.82
+892.64%
-1.62
Change In Payable
0.88
-88.29%
7.47
+185.56%
-8.73
-354.16%
3.44
Change In Account Payable
1.75
-73.55%
6.60
+175.59%
-8.73
-354.16%
3.44
Change In Other Current Liabilities
-17.57
-14.96%
-15.28
+3.18%
-15.79
-101.74%
-7.83
Investing Cash Flow
377.18
+3.78%
363.44
+51.70%
239.57
-1.52%
243.26
Cash Flow From Continuing Investing Activities
377.18
+3.78%
363.44
+51.70%
239.57
-1.52%
243.26
Cash From Discontinued Investing Activities
—
—
0.00
0.00
Net PPE Purchase And Sale
-4.32
-162.37%
-1.65
-604.60%
0.33
+108.32%
-3.92
Purchase Of PPE
-4.32
-156.14%
-1.69
-68.67%
-1.00
+79.53%
-4.88
Sale Of PPE
0.00
-100.00%
0.04
-96.98%
1.32
+37.45%
0.96
Capital Expenditure
-14.32
-749.61%
-1.69
+90.89%
-18.50
-279.00%
-4.88
Net Investment Purchase And Sale
391.50
+154.07%
-724.05
-382.01%
256.75
+122.50%
115.39
Purchase Of Investment
-641.76
+58.39%
-1,542.43
-269.06%
-417.93
+59.46%
-1,030.78
Sale Of Investment
1,033.26
+26.26%
818.38
+21.30%
674.68
-41.14%
1,146.17
Net Business Purchase And Sale
0.00
-100.00%
1,089.14
0.00
-100.00%
131.78
Gain Loss On Sale Of Business
0.00
+100.00%
-200.00
0.00
0.00
Net Intangibles Purchase And Sale
-10.00
0.00
+100.00%
-17.50
0.00
Purchase Of Intangibles
-10.00
0.00
+100.00%
-17.50
0.00
Net Other Investing Changes
—
—
—
131.78
Financing Cash Flow
8.68
-39.93%
14.44
+165.82%
5.43
+131.19%
2.35
Cash Flow From Continuing Financing Activities
8.68
-39.93%
14.44
+165.82%
5.43
+131.19%
2.35
Net Issuance Payments Of Debt
—
0.00
0.00
+100.00%
-0.33
Repayment Of Debt
—
0.00
0.00
+100.00%
-0.33
Long Term Debt Payments
—
0.00
0.00
+100.00%
-0.33
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-0.33
Net Common Stock Issuance
—
—
0.00
0.00
Common Stock Payments
—
—
0.00
0.00
Repurchase Of Capital Stock
—
—
0.00
0.00
Proceeds From Stock Option Exercised
8.68
-39.93%
14.44
+165.82%
5.43
+102.65%
2.68
Changes In Cash
12.88
+207.74%
-11.96
+76.58%
-51.05
+20.06%
-63.87
Beginning Cash Position
76.25
-13.56%
88.20
-36.66%
139.26
-31.44%
203.13
End Cash Position
89.13
+16.90%
76.25
-13.56%
88.20
-36.66%
139.26
Free Cash Flow
-387.29
+1.08%
-391.53
-24.47%
-314.56
-0.06%
-314.36
Income Tax Paid Supplemental Data
0.63
-98.54%
43.15
+2650.16%
1.57
0.00
Amortization Of Securities
-7.20
+50.33%
-14.49
-186.79%
-5.05
-321.62%
-1.20
Change In Income Tax Payable
-0.87
-200.00%
0.87
0.00
0.00
Change In Tax Payable
-0.87
-200.00%
0.87
0.00
0.00
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
Sale Of Business
0.00
-100.00%
1,089.14
0.00
-100.00%
131.78
Cash From Discontinued Financing Activities
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category